{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:49:19Z","timestamp":1789526959669,"version":"build-2803163510"},"reference-count":171,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.chest.2024.11.035","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T16:27:09Z","timestamp":1733934429000},"page":"956-974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Promoting Prevention and Targeting Remission of Asthma"],"prefix":"10.1016","volume":"167","author":[{"given":"Milos","family":"Jesenak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2794-9529","authenticated-orcid":false,"given":"Anna","family":"Bobcakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratko","family":"Djukanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Gaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3087-9530","authenticated-orcid":false,"given":"Nicola A.","family":"Hanania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam G.","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8086-0921","authenticated-orcid":false,"given":"Santiago","family":"Quirce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4115-7376","authenticated-orcid":false,"given":"Dermot","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4852-229X","authenticated-orcid":false,"given":"Wytske","family":"Fokkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8896-495X","authenticated-orcid":false,"given":"Diego","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Hellings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenis","family":"Scadding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Van Staeyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif H.","family":"Bjermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0133-0100","authenticated-orcid":false,"given":"Zuzana","family":"Diamant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-020-00785-1","article-title":"Asthma epidemiology and risk factors","volume":"42","author":"Stern","year":"2020","journal-title":"Semin Immunopathol"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib2","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.jaip.2020.11.053","article-title":"Potential severe asthma hidden in UK primary care","volume":"9","author":"Ryan","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.chest.2024.11.035_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/JAA.S272681","article-title":"Medical costs and productivity loss due to mild, moderate, and severe asthma in the United States","volume":"13","author":"Song","year":"2020","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.chest.2024.11.035_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40413-017-0159-y","article-title":"Severe asthma and quality of life","volume":"10","author":"Hossny","year":"2017","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-52361-9","article-title":"Effect of asthma control on general health-related quality of life in patients diagnosed with adult-onset asthma","volume":"9","author":"Ilmarinen","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2024.11.035_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02058-2018","article-title":"Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report","volume":"53","author":"McDonald","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2024.11.035_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106572","article-title":"Moving towards a treatable traits model of care for the management of obstructive airways diseases","volume":"187","author":"Agusti","year":"2021","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaip.2023.01.011","article-title":"Treatable traits in airway disease: from theory to practice","volume":"11","author":"Agusti","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thoraxjnl-2015-207630","article-title":"Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry","volume":"71","author":"Sweeney","year":"2016","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib12","article-title":"Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review","volume":"7","author":"Patel","year":"2020","journal-title":"BMJ Open Respir Res"},{"issue":"12","key":"10.1016\/j.chest.2024.11.035_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100726","article-title":"Systemic corticosteroids in asthma: a call to action from World Allergy Organization and Respiratory Effectiveness Group","volume":"15","author":"Bleecker","year":"2022","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.alit.2022.09.001","article-title":"The understanding of asthma pathogenesis in the era of precision medicine","volume":"72","author":"Hizawa","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.chest.2024.11.035_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2023.1236977","article-title":"EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care","volume":"4","author":"Hellings","year":"2023","journal-title":"Front Allergy"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"suppl 3","key":"10.1016\/j.chest.2024.11.035_bib18","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.chest.2024.11.035_bib19","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.cgh.2019.02.043","article-title":"Canadian Association of Gastroenterology clinical practice guideline for the management of luminal Crohn\u2019s disease","volume":"17","author":"Panaccione","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4292\/wjgpt.v8.i2.114","article-title":"Inflammatory bowel disease: efficient remission maintenance is crucial for cost containment","volume":"8","author":"Actis","year":"2017","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib21","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jaip.2017.05.001","article-title":"Asthma exacerbations: pathogenesis, prevention, and treatment","volume":"5","author":"Castillo","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib22","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1164\/ajrccm.162.3.9909033","article-title":"Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness","volume":"162","author":"van den Toorn","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.chest.2024.11.035_bib23","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1164\/ajrccm.164.11.2006165","article-title":"Airway inflammation is present during clinical remission of atopic asthma","volume":"164","author":"Van Den Toorn","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00063198-200301000-00003","article-title":"Asthma remission: does it exist?","volume":"9","author":"Van Den Toorn","year":"2003","journal-title":"Curr Opin Pulm Med"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib25","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/all.15566","article-title":"Biomarkers of asthma relapse and lung function decline in adults with spontaneous asthma remission: a population-based cohort study","volume":"78","author":"Tan","year":"2023","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.anai.2023.12.013","article-title":"Analyzing comorbidities and their influence on severe asthma","volume":"132","author":"Mohan","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.rmed.2012.12.015","article-title":"Discordance between asthma control clinical, physiological and inflammatory parameters in mild asthma","volume":"107","author":"Boulay","year":"2013","journal-title":"Respir Med"},{"issue":"20","key":"10.1016\/j.chest.2024.11.035_bib28","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199711133372001","article-title":"Effect of inhaled formoterol and budesonide on exacerbations of asthma","volume":"337","author":"Pauwels","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.chest.2024.11.035_bib29","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","article-title":"Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL Study","volume":"170","author":"Bateman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.chest.2024.11.035_bib30","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1164\/rccm.200904-0616OC","article-title":"Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial","volume":"180","author":"Oborne","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"9347","key":"10.1016\/j.chest.2024.11.035_bib31","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1183\/09031936.06.00137704","article-title":"Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations","volume":"27","author":"Jayaram","year":"2006","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib33","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","article-title":"Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide","volume":"77","author":"Couillard","year":"2022","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40733-015-0013-3","article-title":"Small airway dysfunction and bronchial asthma control: the state of the art","volume":"1","author":"Cottini","year":"2015","journal-title":"Asthma Res Pract"},{"issue":"7","key":"10.1016\/j.chest.2024.11.035_bib35","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(23)00187-X","article-title":"Cough and cough hypersensitivity as treatable traits of asthma","volume":"11","author":"Lai","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"10423","key":"10.1016\/j.chest.2024.11.035_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.chest.2024.11.035_bib37","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib38","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1164\/ajrccm.159.4.9806052","article-title":"Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment","volume":"159","author":"Sont","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib39","doi-asserted-by":"crossref","first-page":"00738","DOI":"10.1183\/23120541.00738-2020","article-title":"Targeting dynamic hyperinflation in moderate-to-severe asthma: a randomised controlled trial","volume":"7","author":"Van Der Meer","year":"2021","journal-title":"ERJ Open Res"},{"issue":"10","key":"10.1016\/j.chest.2024.11.035_bib40","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/all.13806","article-title":"Toward clinically applicable biomarkers for asthma: an EAACI position paper","volume":"74","author":"Diamant","year":"2019","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.chest.2024.11.035_bib41","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S2213-2600(21)00021-7","article-title":"Balancing the needs of the many and the few: where next for adult asthma guidelines?","volume":"9","author":"Shaw","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.chest.2024.11.035_bib42","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1183\/13993003.00055-2016","article-title":"Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease","volume":"47","author":"Pavord","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2024.11.035_bib43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fmed.2017.00158","article-title":"Asthma endotypes and an overview of targeted therapy for asthma","volume":"4","author":"Svenningsen","year":"2017","journal-title":"Front Med"},{"issue":"12","key":"10.1016\/j.chest.2024.11.035_bib44","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1111\/all.15884","article-title":"Eosinophils\u2014from cradle to grave: an EAACI task force paper on new molecular insights and clinical functions of eosinophils and the clinical effects of targeted eosinophil depletion","volume":"78","author":"Jesenak","year":"2023","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.chest.2024.11.035_bib45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/resp.14294","article-title":"Sub-stratification of type-2 high airway disease for therapeutic decision-making: a \u2018bomb\u2019 (blood eosinophils) meets \u2018magnet\u2019 (Feno) framework","volume":"27","author":"Couillard","year":"2022","journal-title":"Respirology"},{"issue":"21","key":"10.1016\/j.chest.2024.11.035_bib46","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1901963","article-title":"Controlled trial of budesonide\u2013formoterol as needed for mild asthma","volume":"380","author":"Beasley","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.chest.2024.11.035_bib47","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2213-2600(20)30053-9","article-title":"Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial","volume":"8","author":"Pavord","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"26","key":"10.1016\/j.chest.2024.11.035_bib48","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.chest.2024.11.035_bib49","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S2213-2600(21)00124-7","article-title":"Baseline Feno as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis","volume":"9","author":"Busse","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"9842","key":"10.1016\/j.chest.2024.11.035_bib50","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.chest.2024.11.035_bib51","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2024.11.035_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.156091","article-title":"IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline","volume":"162","author":"Scott","year":"2023","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2213-2600(20)30397-0","article-title":"Composite type-2 biomarker strategy versus a symptom\u2013risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial","volume":"9","author":"Heaney","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib54","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jaip.2022.12.019","article-title":"A\u00a0randomized trial of a composite T2-biomarker strategy adjusting corticosteroid treatment in severe asthma: a post hoc analysis by sex","volume":"11","author":"Eastwood","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib55","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/all.13629","article-title":"Treatable traits in the European U-BIOPRED adult asthma cohorts","volume":"74","author":"Simpson","year":"2019","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib56","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaci.2018.02.004","article-title":"Obesity and asthma","volume":"141","author":"Peters","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.chest.2024.11.035_bib57","series-title":"Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health","article-title":"Remission","author":"Miller-Keane","year":"2003"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.42347","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"75","author":"Studenic","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"Van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2036.2011.04701.x","article-title":"Review article: defining remission in ulcerative colitis: review: remission in ulcerative colitis","volume":"34","author":"Travis","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.chest.2024.11.035_bib62","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.chest.2024.02.010","article-title":"An update on patient-reported outcomes in asthma","volume":"165","author":"Wu","year":"2024","journal-title":"Chest"},{"issue":"suppl 2","key":"10.1016\/j.chest.2024.11.035_bib63","doi-asserted-by":"crossref","first-page":"i86","DOI":"10.1136\/annrheumdis-2011-200618","article-title":"Defining remission in rheumatoid arthritis","volume":"71","author":"Felson","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib64","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A\u00a0framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"Van Vollenhoven","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.chest.2024.11.035_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.disamonth.2019.02.004","article-title":"A\u00a0comprehensive review and update on ulcerative colitis","volume":"65","author":"Gajendran","year":"2019","journal-title":"Dis Mon"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib66","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12325-021-01946-w","article-title":"Value of remission in patients with rheumatoid arthritis: a targeted review","volume":"39","author":"Ostor","year":"2022","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib68","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2023.04.028","article-title":"Are we ready for asthma remission as a clinical outcome?","volume":"164","author":"Lugogo","year":"2023","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib69","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.chest.2024.11.035_bib70","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"10.1016\/j.chest.2024.11.035_bib71","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe Asthma Network Italy definition of clinical remission in severe asthma: a Delphi consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib72","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1183\/09031936.00121705","article-title":"Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study)","volume":"30","author":"Holm","year":"2007","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib73","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1465-9921-11-106","article-title":"Can AMP induce sputum eosinophils, even in subjects with complete asthma remission?","volume":"11","author":"Volbeda","year":"2010","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086956","article-title":"The course of asthma in young adults: a population-based nine-year follow-up on asthma remission and control","volume":"9","author":"Cazzoletti","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib75","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12931-014-0135-9","article-title":"Asthma incidence, remission, relapse and persistence: a population-based study in southern Taiwan","volume":"15","author":"Wu","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.chest.2024.11.035_bib76","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.rmed.2016.06.017","article-title":"A\u00a012-year prognosis of adult-onset asthma: Sein\u00e4joki Adult Asthma Study","volume":"117","author":"Tuomisto","year":"2016","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.chest.2024.11.035_bib77","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib78","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.chest.2024.11.035_bib79","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2024.11.035_bib80","first-page":"1020","article-title":"Clinical asthma remission obtained with biologics in real life: patients\u2019 prevalence and characteristics","volume":"13","author":"Sposato","year":"2023","journal-title":"J\u00a0Pers Med"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib81","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12931-024-02812-3","article-title":"Barriers to clinical remission in severe asthma","volume":"25","author":"Farinha","year":"2024","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib82","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.anai.2023.08.021","article-title":"Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry","volume":"132","author":"Scelo","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"10.1016\/j.chest.2024.11.035_bib83","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","article-title":"Defining a severe asthma super-responder: findings from a Delphi process","volume":"9","author":"Upham","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.chest.2024.11.035_bib84","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jaip.2023.01.021","article-title":"Super-responders to biologic treatment in type 2\u2014high severe asthma: passing fad or a meaningful phenotype?","volume":"11","author":"Portacci","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.chest.2024.11.035_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107414","article-title":"Biologics in severe asthma: a pragmatic approach for choosing the right treatment for the right patient","volume":"218","author":"Rogers","year":"2023","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib86","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaip.2020.10.035","article-title":"The relationship of asthma biologics to remission for asthma","volume":"9","author":"Menzies-Gow","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.chest.2024.11.035_bib87","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2147\/JAA.S429646","article-title":"Why current therapy does not cure asthma. Is it time to move towards a one health approach?","volume":"16","author":"Rolla","year":"2023","journal-title":"J\u00a0Asthma Allergy"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib88","doi-asserted-by":"crossref","first-page":"00620","DOI":"10.1183\/23120541.00620-2020","article-title":"Remission of adult-onset asthma is rare: a 15-year follow-up study","volume":"6","author":"Almqvist","year":"2020","journal-title":"ERJ Open Res"},{"issue":"6","key":"10.1016\/j.chest.2024.11.035_bib89","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2013-204798","article-title":"The patient perspective on remission in rheumatoid arthritis: \u2018you\u2019ve got limits, but you\u2019re back to being you again.\u2019","volume":"74","author":"Van Tuyl","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib90","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1590\/s0004-2803.202200001-08","article-title":"High prevalence of non-adherence to ulcerative colitis therapy in remission: knowing the problem to prevent loss","volume":"59","author":"Franco","year":"2022","journal-title":"Arq Gastroenterol"},{"issue":"9171","key":"10.1016\/j.chest.2024.11.035_bib91","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(99)01813-9","article-title":"Non-eosinophilic cor ticosteroid unresponsive asthma","volume":"353","author":"Pavord","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.chest.2024.11.035_bib92","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2\u2013driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib93","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3390\/biomedicines11041226","article-title":"T2-low asthma: a discussed but still orphan disease","volume":"11","author":"Peri","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib94","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaip.2020.07.048","article-title":"Multidimensional assessment of asthma identifies clinically relevant phenotype overlap: a cross-sectional study","volume":"9","author":"Han","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib95","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cea.12880","article-title":"Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications","volume":"47","author":"Robinson","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"168","key":"10.1016\/j.chest.2024.11.035_bib96","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0201-2022","article-title":"Phenotype overlap in the natural history of asthma","volume":"32","author":"Ricciardolo","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib97","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1183\/09031936.00073312","article-title":"Smoking and asthma: dangerous liaisons","volume":"41","author":"Polosa","year":"2013","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib98","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.chest.2024.11.035_bib99","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib101","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to anti\u2013IL-5 biologics in severe asthma\u2014a real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib102","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaci.2019.03.013","article-title":"Stratification of asthma phenotypes by airway proteomic signatures","volume":"144","author":"Schofield","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib103","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaip.2021.12.014","article-title":"Controversies in allergy: choosing a biologic for patients with severe asthma","volume":"10","author":"Pavord","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib104","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jaip.2022.11.043","article-title":"Baseline Feno independently predicts the dupilumab response in patients with moderate-to-severe asthma","volume":"11","author":"Pavord","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.chest.2024.11.035_bib105","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1111\/all.15473","article-title":"Biologics and airway remodeling in severe asthma","volume":"77","author":"Varricchi","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.chest.2024.11.035_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2022.1007593","article-title":"Uncontrolled severe T2 asthma: which biological to choose? A biomarker-based approach","volume":"3","author":"L\u00f3pez-Vi\u00f1a","year":"2022","journal-title":"Front Allergy"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib107","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.anai.2022.11.006","article-title":"Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps","volume":"130","author":"Berger","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.chest.2024.11.035_bib108","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2147\/JAA.S413064","article-title":"Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR","volume":"16","author":"Laidlaw","year":"2023","journal-title":"J\u00a0Asthma Allergy"},{"issue":"6","key":"10.1016\/j.chest.2024.11.035_bib109","doi-asserted-by":"crossref","first-page":"476","DOI":"10.18176\/jiaci.0905","article-title":"REDES study: mepolizumab is effective in patients with severe asthma and comorbid nasal polyps","volume":"33","author":"Arismendi","year":"2023","journal-title":"J\u00a0Invest Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib110","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12016-022-08938-w","article-title":"Real-life effectiveness of benralizumab, mepolizumab and omalizumab in severe allergic asthma associated with nasal polyps","volume":"64","author":"Tiotiu","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib111","first-page":"287","article-title":"EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP","volume":"62","author":"Fokkens","year":"2024","journal-title":"Rhinol J"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib112","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.chest.2024.11.035_bib113","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jaip.2023.05.047","article-title":"Response to biologics and clinical remission in the adult German asthma net severe asthma registry cohort","volume":"11","author":"Milger","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.chest.2024.11.035_bib114","doi-asserted-by":"crossref","first-page":"2400316","DOI":"10.1183\/13993003.00316-2024","article-title":"Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies","volume":"64","author":"Wechsler","year":"2024","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib115","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.3390\/ijms24032455","article-title":"Severe asthma remissions induced by biologics targeting IL5\/IL5r: results from a multicenter real-life study","volume":"24","author":"Maglio","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib116","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2022.04.005","article-title":"Can asthma biologics change the course of disease and induce drug-free remission?","volume":"150","author":"Cohn","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.chest.2024.11.035_bib117","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/JAA.S340684","article-title":"Feasibility of discontinuing biologics in severe asthma: an algorithmic approach","volume":"14","author":"Hamada","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"issue":"5","key":"10.1016\/j.chest.2024.11.035_bib118","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/all.13678","article-title":"Omalizumab discontinuation in children with severe allergic asthma: an observational real-life study","volume":"74","author":"Deschildre","year":"2019","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib119","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00396-2021","article-title":"Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)","volume":"59","author":"Moore","year":"2022","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib120","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/cea.13561","article-title":"Matching-adjusted comparison of oral corticosteroid reduction in asthma: systematic review of biologics","volume":"50","author":"Bourdin","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.chest.2024.11.035_bib121","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221107313","article-title":"Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies","volume":"16","author":"Casale","year":"2022","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib122","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"26","key":"10.1016\/j.chest.2024.11.035_bib123","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10056","key":"10.1016\/j.chest.2024.11.035_bib124","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"10209","key":"10.1016\/j.chest.2024.11.035_bib125","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.chest.2024.11.035_bib126","series-title":"StatPearls","article-title":"Prevention strategies","author":"Kisling","year":"2023"},{"issue":"10254","key":"10.1016\/j.chest.2024.11.035_bib127","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(20)31861-4","article-title":"Primary prevention of asthma: from risk and protective factors to targeted strategies for prevention","volume":"396","author":"Von Mutius","year":"2020","journal-title":"Lancet"},{"issue":"01","key":"10.1016\/j.chest.2024.11.035_bib128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5414\/ALX02303E","article-title":"S3 guideline allergy prevention","volume":"6","author":"Kopp","year":"2022","journal-title":"Allergol Sel"},{"key":"10.1016\/j.chest.2024.11.035_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2023.1291185","article-title":"Pre-asthma: a useful concept for prevention and disease-modification? A EUFOREA paper. Part 1\u2014allergic asthma","volume":"4","author":"Scadding","year":"2024","journal-title":"Front Allergy"},{"issue":"11","key":"10.1016\/j.chest.2024.11.035_bib130","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/children8111067","article-title":"Current insights into atopic march","volume":"8","author":"Tsuge","year":"2021","journal-title":"Children"},{"issue":"9","key":"10.1016\/j.chest.2024.11.035_bib131","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/1744666X.2020.1816825","article-title":"Atopic phenotypes and their implication in the atopic march","volume":"16","author":"Custovic","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"10.1016\/j.chest.2024.11.035_bib132","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/cea.13156","article-title":"New insights into the phenotypes of atopic dermatitis linked with allergies and asthma in children: an overview","volume":"48","author":"Amat","year":"2018","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.chest.2024.11.035_bib133","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1111\/all.15295","article-title":"Allergen immunotherapy for asthma prevention: a systematic review and meta-analysis of randomized and non-randomized controlled studies","volume":"77","author":"Farraia","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.chest.2024.11.035_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107125","article-title":"Allergen immunotherapy for allergic asthma: the future seems bright","volume":"210","author":"Diamant","year":"2023","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.chest.2024.11.035_bib135","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/pai.12807","article-title":"EAACI guidelines on allergen immunotherapy: prevention of allergy","volume":"28","author":"Halken","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"issue":"8","key":"10.1016\/j.chest.2024.11.035_bib136","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1398-9995.2007.01451.x","article-title":"Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study","volume":"62","author":"Jacobsen","year":"2007","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.reval.2023.103577","article-title":"Impact de l\u2019immunoth\u00e9rapie sublinguale (ITSL) sur l\u2019apparition de l\u2019asthme chez les patients atteints de rhinite allergique: r\u00e9sultats de l\u2019\u00e9tude EfficAPSI","volume":"63","author":"Devillier","year":"2023","journal-title":"Rev Fr Allergol"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib138","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/all.13213","article-title":"Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis","volume":"73","author":"Zielen","year":"2018","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib139","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/all.14020","article-title":"The moderating role of allergy immunotherapy in asthma progression: results of a population-based cohort study","volume":"75","author":"Schmitt","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.chest.2024.11.035_bib140","article-title":"Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: results from the REACT study, a retrospective cohort study","volume":"13","author":"Fritzsching","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib141","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jaci.2023.02.024","article-title":"Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: subgroup analyses of the REACT study","volume":"152","author":"Contoli","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib142","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.alit.2024.05.005","article-title":"Allergen immunotherapy in asthma","volume":"73","author":"Nakagome","year":"2024","journal-title":"Allergol Int"},{"key":"10.1016\/j.chest.2024.11.035_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107361","article-title":"EUFOREA pocket guide on the diagnosis and management of asthma: an educational and practical tool for general practitioners, non-respiratory physicians, paramedics and patients","volume":"218","author":"Diamant","year":"2023","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.chest.2024.11.035_bib144","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/all.15835","article-title":"How does allergen immunotherapy-induced tolerance improve the airway epithelial barrier function: a mechanistical-driven hypothesis","volume":"78","author":"Pfaar","year":"2023","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.chest.2024.11.035_bib145","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00446-2022","article-title":"Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study","volume":"60","author":"Woehlk","year":"2022","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.chest.2024.11.035_bib146","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.202209-1708OC","article-title":"Allergen immunotherapy enhances airway epithelial antiviral immunity in patients with allergic asthma (VITAL study): a double-blind randomized controlled trial","volume":"207","author":"Woehlk","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib147","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/cea.14575","article-title":"Allergen immunotherapy for the prevention and treatment of asthma","volume":"55","author":"Batard","year":"2025","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib148","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","article-title":"Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial","volume":"151","author":"Corren","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib149","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaci.2022.08.026","article-title":"Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events","volume":"151","author":"Geba","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.chest.2024.11.035_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106228","article-title":"Preventing asthma in high risk kids (PARK) with omalizumab: design, rationale, methods, lessons learned and adaptation","volume":"100","author":"Phipatanakul","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib151","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1038\/s41467-021-22834-5","article-title":"Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice","volume":"12","author":"Conde","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100634","article-title":"The role of environmental allergen control in the management of asthma","volume":"15","author":"Kalayci","year":"2022","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib153","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaip.2017.05.019","article-title":"Sensitization and exposure to pets: the effect on asthma morbidity in the US population","volume":"6","author":"Gergen","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.chest.2024.11.035_bib154","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.127.5.1565","article-title":"Effect of pet removal on pet\u00a0allergic asthma","volume":"127","author":"Shirai","year":"2005","journal-title":"Chest"},{"issue":"7166","key":"10.1016\/j.chest.2024.11.035_bib155","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.317.7166.1105","article-title":"House dust mite control measures in the management of asthma: meta-analysis","volume":"317","author":"Gotzsche","year":"1998","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib156","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1164\/rccm.201609-1966OC","article-title":"Preventing severe asthma exacerbations in children. A randomized trial of mite-impermeable bedcovers","volume":"196","author":"Murray","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.chest.2024.11.035_bib157","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/thx.2006.070847","article-title":"Effects on patients with asthma of eradicating visible indoor mould: a randomised controlled trial","volume":"62","author":"Burr","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.chest.2024.11.035_bib158","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fped.2019.00028","article-title":"Severe asthma and allergy: a pediatric perspective","volume":"7","author":"Arasi","year":"2019","journal-title":"Front Pediatr"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib159","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/all.13072","article-title":"Allergy in severe asthma","volume":"72","author":"Del Giacco","year":"2017","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.chest.2024.11.035_bib160","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1111\/all.15817","article-title":"Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: an EAACI position paper","volume":"78","author":"Kappen","year":"2023","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib161","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2021-001277","article-title":"Diagnosis and management of asthma in children","volume":"6","author":"Martin","year":"2022","journal-title":"BMJ Paediatr Open"},{"issue":"8","key":"10.1016\/j.chest.2024.11.035_bib162","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/02770903.2020.1753210","article-title":"Parental perception of a picture-based chronic asthma care management tool in an urban pediatric emergency department","volume":"58","author":"Pade","year":"2021","journal-title":"J\u00a0Asthma"},{"issue":"3","key":"10.1016\/j.chest.2024.11.035_bib163","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/children9030332","article-title":"Heterogeneous condition of asthmatic children patients: a narrative review","volume":"9","author":"Caruso","year":"2022","journal-title":"Children"},{"key":"10.1016\/j.chest.2024.11.035_bib164","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fped.2014.00077","article-title":"Pulmonary manifestations of primary immunodeficiency disorders in children","volume":"2","author":"Jesenak","year":"2014","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.chest.2024.11.035_bib165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2015.02.024","article-title":"Association between respiratory infections in early life and later asthma is independent of virus type","volume":"136","author":"B\u00f8nnelykke","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib166","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/endocrines1020012","article-title":"Steroid-induced iatrogenic adrenal insufficiency in children: a literature review","volume":"1","author":"Akahoshi","year":"2020","journal-title":"Endocrines"},{"issue":"6","key":"10.1016\/j.chest.2024.11.035_bib167","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1164\/rccm.202009-3537OC","article-title":"Associations between\u00a0inhaled corticosteroid use in the first 6 years of life and obesity-related traits","volume":"204","author":"Kun\u00f8e","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"24","key":"10.1016\/j.chest.2024.11.035_bib168","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.chest.2024.11.035_bib169","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3390\/children9081253","article-title":"Novel lung growth strategy with biological therapy targeting airway remodeling in childhood bronchial asthma","volume":"9","author":"Tsuge","year":"2022","journal-title":"Children"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib170","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaci.2010.07.011","article-title":"Long-term studies of the natural history of asthma in childhood","volume":"126","author":"Bisgaard","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.chest.2024.11.035_bib171","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1155\/2010\/318029","article-title":"Airway remodelling in asthma: from benchside to clinical practice","volume":"17","author":"Bergeron","year":"2010","journal-title":"Can Respir J"},{"issue":"11","key":"10.1016\/j.chest.2024.11.035_bib172","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045728","article-title":"Natural history and associated early life factors of childhood asthma: a population registry-based cohort study in Denmark","volume":"11","author":"Chen","year":"2021","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.chest.2024.11.035_bib173","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2352-4642(22)00224-3","article-title":"Need for a consensus definition of remission in paediatric asthma","volume":"6","author":"Corbett","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"2","key":"10.1016\/j.chest.2024.11.035_bib174","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/ACI.0000000000000819","article-title":"Current strategies for phenotyping and managing asthma in preschool children","volume":"22","author":"Feleszko","year":"2022","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224056174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224056174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T20:04:14Z","timestamp":1747857854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369224056174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":171,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0012369224056174"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2024.11.035","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Promoting Prevention and Targeting Remission of Asthma","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2024.11.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}